 |
HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide.
The nordicPRO-C3â„¢ biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to helping patients in a precision medicine driven approach, and our Platform provides the quality needed for regulatory approval.
Nordic Bioscience's scientists have over that last 10 years published more than 250 scientific papers on PRO-C3 making us the leading place for research within PRO-C3 and fibrotic related diseases.
PRO-C3 is the first of the Nordic Bioscience-biomarkers from our fibrosis panel which has been CE-approved. 40% of deaths in the western world are associated with alterations of organs such as the liver, and we provide the tools to quantify this. These are the tools of modern clinical chemistry.
"The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients." said Morten Karsdal, CEO of Nordic Bioscience.
About PRO-C3
PRO-C3 was invented by Nordic Bioscience and has up until now been available as a service performed in Nordic Bioscience's laboratory in Denmark using the nordicPRO-C3â„¢ test. The Elecsys PRO-C3 test is developed under a license agreement between Nordic Bioscience and Roche Diagnostics. For more information including scientific information on PRO-C3 see https://www.nordicbioscience.com/technology/biomarkers/pro-c3-nordicpro-c3
About Nordic Bioscience
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at https://www.nordicbioscience.com
For product related inquires please use https://www.nordicbioscience.com/contact
HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide.
The nordicPRO-C3â„¢ biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to helping patients in a precision medicine driven approach, and our Platform provides the quality needed for regulatory approval.
Nordic Bioscience's scientists have over that last 10 years published more than 250 scientific papers on PRO-C3 making us the leading place for research within PRO-C3 and fibrotic related diseases.
PRO-C3 is the first of the Nordic Bioscience-biomarkers from our fibrosis panel which has been CE-approved. 40% of deaths in the western world are associated with alterations of organs such as the liver, and we provide the tools to quantify this. These are the tools of modern clinical chemistry.
"The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients." said Morten Karsdal, CEO of Nordic Bioscience.
About PRO-C3
PRO-C3 was invented by Nordic Bioscience and has up until now been available as a service performed in Nordic Bioscience's laboratory in Denmark using the nordicPRO-C3â„¢ test. The Elecsys PRO-C3 test is developed under a license agreement between Nordic Bioscience and Roche Diagnostics. For more information including scientific information on PRO-C3 see https://www.nordicbioscience.com/technology/biomarkers/pro-c3-nordicpro-c3
About Nordic Bioscience
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at https://www.nordicbioscience.com
For product related inquires please use https://www.nordicbioscience.com/contact
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers
BANGKOK, Jan. 14, 2026 /PRNewswire/ -- The inaugural "Moyom Biotech • Aphranel Global Expert Advisory Panel • Thailand Anatomy Exchange Conference" was successfully convened in Thailand. This high-level forum gathered leading experts from multiple Asia-Pacific countries.
Through this concentrated academic dialogue, Aphranel reaffirmed to the industry a clear guiding principle: to return aesthetic medicine to its medical foundation and to safeguard the safe application of regenerative materials through meticulous anatomical science.
Dialogue Between Chinese and International Experts Explores "Regeneration"
The significance of regenerative materials extends beyond composition—it reflects a deep understanding of human anatomy. Using detailed specimens and high-definition imaging, a Chinese–Thai expert team led by Professor Luo Shengkang from Guangdong Second Provincial General Hospital conducted a layer-by-layer study of facial anatomy.
Their analysis of tissue planes, ligaments, and vasculature revealed how Calcium Hydroxylapatite (CaHA) functions as a "collagen-initiating scaffold" within specific anatomical layers.
Dr. Benrita from Ramathibodi Hospital, Mahidol University, Thailand, provided an international perspective, revealing the application logic and evolving trends of regenerative materials across different ethnicities and aesthetic systems. The convergence of Eastern and Western viewpoints elevated the concept of "regeneration" beyond mere technique, advancing it to the construction of holistic medical aesthetics.
Pooling Global Expertise, the MagiC Concept Sets Sail
A major highlight of the conference was the launch of the MagiC Concept Global Expert Advisory Panel, an academic community in regenerative medicine founded by Aphranel and leading global scholars. Dedicated to advancing anatomy-based injection protocols, clinical solutions, and efficacy evaluation systems, the panel aims to enhance the safety, precision, and predictability of regenerative medical practice.
True regeneration is far more than simply stimulating collagen production. It is about reactivating the skin's inherent repair mechanisms through the synergy of material science and clinical technique, achieving a renewal of both tissue function and aesthetic form. As a domestically originated and researched regenerative product, Aphranel has consistently championed this philosophy.
From laboratory research to clinical validation, and from physician education to patient communication, Aphranel has remained steadfast in its original commitment of "Research for Medicine, Medicine for Aesthetics." The company is dedicated to long-term academic development and ecosystem cultivation.
The launch of the MagiC Concept Global Expert Advisory Panel marks a new phase of global collaboration for Aphranel, driving deeper research in regenerative material science, professional development, and the advancement of regenerative aesthetic medicine in China.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Aphranel Convenes Cadaver Dissection Class in Thailand Successfully
